Treatment of Breast Cancer Using Multistage Delivery of PI3K/mTOR Inhibitors

被引：0
|
作者：
Blanco, E.
Sangai, T.
Martinez, J. O.
Meric-Bernstam, F.
Ferrari, M.
机构：
[1] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P6-14-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-14-10
引用
收藏
页数：1
相关论文
共 50 条
  • [11] The Impact of PI3K Inhibitors for the Treatment of Patients with Breast Cancer
    Traina, Tiffany A.
    ONCOLOGY-NEW YORK, 2020, 34 (01): : 28 - 31
  • [12] Potential role of PI3K inhibitors in the treatment of breast cancer
    Carvalho, Silvia
    Schmitt, Fernando
    FUTURE ONCOLOGY, 2010, 6 (08) : 1251 - 1263
  • [13] Novel agents and associated toxicities of inhibitors of the PI3K/Akt/mTOR pathway for the treatment of breast cancer
    Chia, S.
    Gandhi, S.
    Joy, A. A.
    Edwards, S.
    Gorr, M.
    Hopkins, S.
    Kondejewski, J.
    Ayoub, J. P.
    Califaretti, N.
    Rayson, D.
    Dent, S. F.
    CURRENT ONCOLOGY, 2015, 22 (01) : 33 - 48
  • [14] Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer
    Ren, Guosheng
    Shao, Zhimin
    Wu, Jong
    Xu, Binghe
    Ma, Fei
    Mo, Hongnan
    Ying, Jianming
    Yin, Yongmei
    Cui, Jiuwei
    Cui, Wei
    Chen, Qianjun
    Chen, Yiding
    Dai, Huaping
    Di, Lijun
    Feng, Jifeng
    Hao, Chunfang
    Hua, Hua
    Huang, Jian
    Hu, Xichun
    Jiao, Yuchen
    Jin, Feng
    Li, Hongyuan
    Li, Man
    Liao, Ning
    Li, Naishi
    Liu, Qiang
    Li, Ting
    Liu, Yunjiang
    Liu, Zhenzhen
    Luan, Tianyan
    Meng, Yan
    Ouyang, Nengtai
    Ouyang, Quchang
    Qian, Haili
    Song, Chuangui
    Sun, Tao
    Sun, Tong
    Shi, Yehui
    Shi, Yanxia
    Tang, Jinhai
    Tong, Zhongsheng
    Wang, Haibo
    Wang, Jiayu
    Wang, Shu
    Wang, Shusen
    Wang, Tao
    Wang, Xiaojia
    Wang, Yongsheng
    Yang, Jin
    Yu, Keda
    CANCER INNOVATION, 2022, 1 (01): : 25 - 54
  • [15] Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer
    Chen, Jiezhong
    CURRENT CANCER DRUG TARGETS, 2013, 13 (02) : 117 - 120
  • [16] PI3K Inhibitors in Breast Cancer Therapy
    Ellis, Haley
    Ma, Cynthia X.
    CURRENT ONCOLOGY REPORTS, 2019, 21 (12)
  • [17] PI3K Inhibitors in Breast Cancer Therapy
    Haley Ellis
    Cynthia X. Ma
    Current Oncology Reports, 2019, 21
  • [18] G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer
    Yim, Christina Y.
    Bikorimana, Emmanuel
    Khan, Ema
    Warzecha, Joshua M.
    Shin, Leah
    Rodriguez, Jennifer
    Dmitrovsky, Ethan
    Freemantle, Sarah J.
    Spinella, Michael J.
    CELL CYCLE, 2017, 16 (21) : 2146 - 2155
  • [19] Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
    Ghayad, Sandra E.
    Cohen, Pascale A.
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2010, 5 (01) : 29 - 57
  • [20] PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer
    Altundag, Kadri
    MEDICAL ONCOLOGY, 2024, 41 (11)
12345